HALO Macrodissection Solutions Brochure
Learn more about the automated workflow and benefits of HALO Macrodissection Solutions
HALO Macrodissection Solutions Brochure Read More »
HALO AP
AI and Digital Pathology in Personalized Medicine: The Past, Present, and Future of Breast Cancer Care
AI-powered digital pathology is redefining modern cancer care by extending clinical-grade insights beyond the microscope and enabling standardized, pixel-level analysis to support scalable cancer diagnostics anytime, anywhere.
Indica Labs Surpasses 3,000 Deployments of HALO Digital Pathology Software Worldwide Since 2013
Albuquerque, NM, March 3, 2026 – Indica Labs, the global leader in AI-powered digital pathology software and services, today announces surpassing the 3,000th installation of HALO software worldwide.
KLAS Recognition as a Catalyst for What Comes Next
We are proud to mark a significant milestone: HALO AP® earned the highest overall customer rating in the 2026 KLAS Global Software report for digital pathology. Because KLAS distinction is driven entirely by direct customer feedback, this recognition reflects the real-world performance, reliability, and impact of our platform in daily pathology practice.
KLAS Recognition as a Catalyst for What Comes Next Read More »
HALO AP 2.5 Sneak Peek Webinar
16 April 2026 | Learn about the exciting new features in the 2.5 versions of HALO AP®!
HALO AP 2.5 Sneak Peek Webinar Read More »
HALO AP® is Now Rated in Best in KLAS®: Earning ‘A’ Grades in All Categories
Albuquerque, NM, February 12, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced recognition by KLAS for top customer-rated performance in the European digital pathology market.
HALO AP® is Now Rated in Best in KLAS®: Earning ‘A’ Grades in All Categories Read More »
Indica Labs Sets New Standard for Molecular Testing in Breast Cancer with Expansion of AI Macrodissection Portfolio
Albuquerque, NM, February 10, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the expansion of its macrodissection portfolio with the launch of Breast Macrodissect AI . The suite now includes advanced algorithms for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and breast cancer, with prostate cancer planned for release in early 2026.
Looking Back: Reviewing 2025 at Indica Labs
As we reach the end of 2025, the Indica Labs team extends our sincere thanks to the customers and collaborators who helped make this year one of remarkable innovation, growth, and scientific achievement.
Looking Back: Reviewing 2025 at Indica Labs Read More »
Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets
Albuquerque, NM, December 17, 2025 – Indica Labs, the global leader in AI-powered digital pathology, announced today that clinical revenue growth rate for HALO AP® is up 260% since 2023 and recurring revenue for 2025 shows a 200% increase year-over-year, reinforcing its position as a market leader in digital pathology diagnostics.
Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets Read More »
Indica Labs Receives FDA Clearance for Enterprise Digital Pathology Platform with Industry Leading DICOM-Compatible Aperio Scanner from Leica Biosystems
ALBUQUERQUE, NM, and VISTA, CA, December 3, 2025 – Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announced today that the Food and Drug Administration (FDA) has issued a 510(k) clearance for the enterprise digital pathology platform HALO AP Dx in conjunction with Leica Biosystems Aperio GT 450 DX Scanner for in-vitro diagnostic use.